Lyon published a research report stating thatshamrock7videopoker, Baiji Shenzhou's sales in the first quarter of fiscal year 2024 increased by 67% year-on-yearshamrock7videopoker.9%, performance exceeding market expectations. The bank believes that sales of BTK inhibitors independently developed by Baiji Shenzhou are still the main driving force for its performance, with sales of related inhibitors increasing by 131.1% year-on-year.

According to the bank's statistics, the market share of the above inhibitors in the United States has increased to 24.1%, compared with 19.1% and 21.2% in the third and fourth quarters of last year. The bank also believes that the progress of the company's BCL-2 and BTK CDAC products this year is worthy of attention. Lyon adjusted its performance forecast for Baiji Shenzhou and raised its H-share target price from HK$138.5 to HK$139.7, reiterating its "Buy" rating.